Related Experiment Video
Updated: Feb 4, 2026
06:54
Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
14.4K
LncRNAs in TGF-β-Driven Tissue Fibrosis
Patrick Ming-Kuen Tang1,2, Ying-Ying Zhang3,4, Hui-Yao Lan5
1Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, Lui Che Woo Institute of Innovative Medicine, Shenzhen Research Institute, The Chinese University of Hong Kong, Hong Kong 999077, China. patrick.tang@cuhk.edu.hk.
Non-Coding RNA
|October 6, 2018
Summary
Long noncoding RNAs (lncRNAs) are increasingly recognized for their role in fibrogenesis, a process driven by transforming growth factor-β (TGF-β). This review explores lncRNAs in TGF-β1-driven fibrosis and their therapeutic potential.
Area of Science:
- Molecular Biology
- Cell Biology
- Pathology
Background:
- Transforming growth factor-β (TGF-β) is a key driver of tissue fibrosis, mediating processes like extracellular matrix accumulation and various mesenchymal transitions.
- While microRNAs' roles in TGF-β-mediated scarring are known, the involvement of long noncoding RNAs (lncRNAs) in fibrogenesis is less understood.
- Emerging research highlights lncRNAs' involvement in diverse diseases, including fibrotic conditions.
Purpose of the Study:
- To review current knowledge on the role of lncRNAs in TGF-β1-driven tissue fibrosis.
- To discuss the potential of lncRNAs as therapeutic targets for chronic fibrotic diseases.
Main Methods:
- Literature review of studies investigating lncRNAs in TGF-β1 signaling and fibrotic diseases.
- Synthesis of findings on lncRNA mechanisms in fibrosis.
- Analysis of therapeutic strategies targeting lncRNAs in fibrosis.
Main Results:
- lncRNAs play significant roles in TGF-β1-mediated fibrotic processes.
- Specific lncRNAs have been identified as regulators of fibrosis.
- lncRNAs offer potential as biomarkers and therapeutic targets.
Conclusions:
- lncRNAs are critical players in TGF-β1-induced fibrosis.
- Targeting lncRNAs presents a promising avenue for treating chronic fibrotic diseases.
- Further research is needed to fully elucidate lncRNA functions and therapeutic applications.
Related Concept Videos
01:16TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
01:23Cystic Fibrosis: Pathogenesis
885
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
885
01:24Cystic Fibrosis: Management
543
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
543
01:27ATP Driven Pumps I: An Overview
9.9K
ATP-driven pumps, also known as transport ATPases, are integral membrane proteins. They have binding sites for ATP located on the membrane's cytosolic side and the ion-conducting domain in the transmembrane region. These pumps use the free energy released from ATP hydrolysis to move the solutes across cell membranes against an electrochemical gradient.
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
There are four main types of ATP-driven pumps - P-type, V-type, F-type, and ABC transporter. All these pumps are of varying complexities and...
9.9K
02:03Xylem and Transpiration-driven Transport of Resources
26.8K
The xylem of vascular plants distributes water and dissolved minerals that are taken up by the roots to the rest of the plant. The cells that transport xylem sap are dead upon maturity, and the movement of xylem sap is a passive process.
26.8K
01:34ATP Driven Pumps II: P-type Pumps
6.4K
The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V.
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...
6.4K